At a glance
ClinicalIndex Comparison Record- ✓Confirmed solid malignant tumor (excluding germ cell, leukemia, lymphoma)
- ✓1-3 hepatic metastases confirmed by pre-therapeutic MRI
- ✓Indication for SBRT of 1-3 hepatic metastases
- ✓Maximum diameter each metastasis ≤5 cm; if 3 metastases sum of diameters ≤12 cm
- ✕Primary liver cancer (HCC, CCC)
- ✕History of liver transplantation
- ✕Impairment of liver function contraindicating radiotherapy
- ✕Active acute hepatic/biliary infection (hepatitis, cholangitis, cholecystitis)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases - MAESTRO -
In Brief
A Phase 2 clinical trial evaluating ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT) and MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy) for Hepatic Metastasis. Currently recruiting, targeting 90 participants across 1 site.
Detailed Summary
Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients with hepatic oligometastases. Liver metastases often occur in close proximity to radiosensitive organs at risk (OARs). This limits the possibility to apply sufficiently high doses needed for optimal local control. MR-guided radiotherapy (MRgRT) is expected to hold potential to improve hepatic SBRT by offering superior soft-tissue contrast for enhanced target identification as well as the benefit of daily real-time adaptive treatment. The MAESTRO trial therefore aims to assess the potential advantages of adaptive, gated MR-guided SBRT (MRgSBRT) compared to conventional SBRT at a standard linac using an ITV (internal target volume) approach (ITV-SBRT).
Study Details
Timeline
Interventions
ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)